%0 Journal Article %T When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer? %A Gong, Jun %A Chao, Joseph %J Annals of Translational Medicine %D 2019 %B 2019 %9 %! When survival curves cross: are we at a crossroads of immunotherapy in gastric cancer? %K %X The first U.S. Food and Drug Administration (FDA) approval of a programmed cell death protein (PD-1) inhibitor specifically for advanced gastroesophageal cancer occurred with the passing of pembrolizumab on September 22, 2017 (1). %U https://atm.amegroups.org/article/view/24280 %P S35 %@ 2305-5847